Pleiotropic effects of atorvastatin on monocytes in atherosclerotic patients

Journal of Clinical Pharmacology

Volumn 50, Issue 3, 2010, Pages 311-319

  Wang, Zhi Hao ^a   Liu, Xiao Lin ^b   Zhong, Ming ^a   Zhang, Li Ping ^c   Shang, Yuan Yuan ^a   Hu, Xiao Yan ^c   Li, Li ^a   Zhang, Yun ^a   Deng, Jing Ti ^c   Zhang, Wei ^a  

^a SHANDONG UNIVERSITY   (China)

^b BINZHOU MEDICAL UNIVERSITY   (China)

^c SHANDONG UNIVERSITY   (China)

Author keywords

Atherosclerosis; Atorvastatin; Monocyte; Pleiotropic effects

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ATORVASTATIN; CYTOSOL AMINOPEPTIDASE; DIPEPTIDYL PEPTIDASE IV; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 8 RECEPTOR; INTERSTITIAL COLLAGENASE; LEGUMAIN; LEPTIN RECEPTOR; MICROSOMAL AMINOPEPTIDASE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PEPTIDASE; PROLYL ENDOPEPTIDASE; PROTEIN P53; PROTEIN TYROSINE PHOSPHATASE; TRIPEPTIDYL PEPTIDASE II; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FOAM CELL; FOLLOW UP; GENE EXPRESSION; GENE TARGETING; HUMAN; INFLAMMATION; LIPID ANALYSIS; MACROPHAGE; MALE; MONOCYTE; PATIENT COMPLIANCE; PLEIOTROPY; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADMINISTRATION, ORAL; ANTICHOLESTEREMIC AGENTS; ANTIGENS, CD13; APOPTOSIS; ATHEROSCLEROSIS; CORONARY DISEASE; CYSTEINE ENDOPEPTIDASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION; HEPTANOIC ACIDS; HUMANS; LIPID METABOLISM; MALE; MATRIX METALLOPROTEINASE 1; MIDDLE AGED; MONOCYTES; PYRROLES; RECEPTORS, LEPTIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SERINE ENDOPEPTIDASES; TIME FACTORS; TREATMENT OUTCOME;

EID: 77649203108     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009340889     Document Type: Article

References (35)

1. Linton MF, Fazio S. Macrophages, inflammation, and atherosclerosis. Int J Obes Relat Metab Disord. 2003 ; 27: S35 - S40.
2. Vaughan CJ, Murphy MB, Buckley BM Statins do more than just lower cholesterol. Lancet. 1996 ; 348: 1079-1082.
3. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005 ; 45: 89-118.
4. Albert MA, Danielson E., Rifai N., et al. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001 ; 286: 64-70.
5. Ky B., Burke A., Tsimikas S., et al. The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans. J Am Coll Cardiol. 2008 ; 51: 1653-1662.
6. Bourcier T., Libby P. HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler Thromb Vasc Biol. 2000 ; 20: 556-562.
7. Nissen SE, Tuzcu EM, Schoenhagen P., et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004 ; 291: 1071-1080. (Pubitemid 38541684)
8. Cannon CP, Braunwald E., McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004 ; 350: 1495-1504.
9. Libby P. Inflammation in atherosclerosis. Nature. 2002 ; 420: 868-874.
10. Livak KJ, Schmittgen TD Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001 ; 25: 402-408.
11. Mercer J., Figg N., Stoneman V., et al. Endogenous p53 protects vascular smooth muscle cells from apoptosis and reduces atherosclerosis in ApoE knockout mice. Circ Res. 2005 ; 96: 667-674.
12. Sanz-Gonzlez SM, Barqun L., Garca-Cao I., et al. Increased p53 gene dosage reduces neointimal thickening induced by mechanical injury but has no effect on native atherosclerosis. Cardiovasc Res. 2007 ; 75: 803-812.
13. van Vlijmen BJ, Gerritsen G., Franken AL, et al. Macrophage p53 deficiency leads to enhanced atherosclerosis in APOE*3-Leiden transgenic mice. Circ Res. 2001 ; 88: 780-786.
14. Lalloyer F., Fivet C., Lestavel S., et al. The RXR agonist bexarotene improves cholesterol homeostasis and inhibits atherosclerosis progression in a mouse model of mixed dyslipidemia. Arterioscler Thromb Vasc Biol. 2006 ; 26: 2731-2737.
15. Kramer W., Girbig F., Corsiero D., et al. Aminopeptidase N (CD13) is a molecular target of the cholesterol absorption inhibitor ezetimibe in the enterocyte brush border membrane. J Biol Chem. 2005 ; 280: 1306-1320.
16. Taleb S., Herbin O., Ait-Oufella H., et al. Defective leptin/leptin receptor signaling improves regulatory T cell immune response and protects mice from atherosclerosis. Arterioscler Thromb Vasc Biol. 2007 ; 27: 2691-2698.
17. Papaspyridonos M., Smith A., Burnand KG, et al. Novel candidate genes in unstable areas of human atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2006 ; 26: 1837-1844.
18. McKay RM, McKay JP, Suh JM, et al. Tripeptidyl peptidase II promotes fat formation in a conserved fashion. EMBO Rep. 2007 ; 8: 1183-1189.
19. Kawai M., Hara Y., Miyazato I., et al. Novel, aberrantly truncated isoform of serum CD13 in a family with high serum aminopeptidase N (CD13) activity. Clin Chem. 2001 ; 47: 223-230.
20. Cavasin MA, Rhaleb NE, Yang XP, Carretero OA Prolyl oligopeptidase is involved in release of the antifibrotic peptide Ac-SDKP. Hypertension. 2004 ; 43: 1140-1145.
21. Charo IF, Ransohoff RM The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med. 2006 ; 354: 610-621.
22. Seljeflot I., Tonstad S., Hjermann I., et al. Reduced expression of endothelial cell markers after 1 year treatment with simvastatin and atorvastatin in patients with coronary heart disease. Atherosclerosis. 2002 ; 162: 179-185.
23. Hackman A., Abe Y., Insull W. Jr, et al. Levels of soluble cell adhesion molecules in patients with dyslipidemia. Circulation. 1996 ; 93: 1334-1338.
24. Papadopoulou C., Corrigall V., Taylor PR, et al. The role of the chemokines MCP-1, GRO-alpha, IL-8 and their receptors in the adhesion of monocytic cells to human atherosclerotic plaques. Cytokine. 2008 ; 43: 181-186.
25. Fukuhara A., Matsuda M., Nishizawa M., et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005 ; 307: 426-430. (Pubitemid 40139988)
26. Zhong M., Tan HW, Gong HP, et al. Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis. Clin Endocrinol (Oxf). 2008 ; 69: 878-884.
27. Dahl TB, Yndestad A., Skjelland M., et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation. 2007 ; 115: 972-980.
28. Pftzner A., Hanefeld M., Lobben G., et al. Visfatin: a putative biomarker for metabolic syndrome is not influenced by pioglitazone or simvastatin treatment in nondiabetic patients at cardiovascular risk-results from the PIOSTAT study. Horm Metab Res. 2007 ; 39: 764-768.
29. M?Currency signuser W., Perwitz N., Meier B., et al. Direct adipotropic actions of atorvastatin: differentiation state-dependent induction of apoptosis, modulation of endocrine function, and inhibition of glucose uptake. Eur J Pharmacol. 2007 ; 564: 37-46.
30. Blackie JA, Bloomer JC, Brown MJ, et al. The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2. Bioorg Med Chem Lett. 2003 ; 13: 1067-1070.
31. Li W., Kornmark L., Jonasson L., et al. Cathepsin L is significantly associated with apoptosis and plaque destabilization in human atherosclerosis. Atherosclerosis. 2009 ; 202: 92-102.
32. Kawai M., Hara Y., Kubota T., et al. A family with high serum leucine aminopeptidase activity derived from a novel variant CD13. Clin Chem. 1998 ; 44: 215-220.
33. Stavropoulou V., Vasquez V., Cereser B., et al. TPPII promotes genetic instability by allowing the escape from apoptosis of cells with activated mitotic checkpoints. Biochem Biophys Res Commun. 2006 ; 346: 415-425.
34. Ban K., Noyan-Ashraf MH, Hoefer J., et al. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation. 2008 ; 117: 2340-2350.
35. Gaggar A., Jackson PL, Noerager BD, et al. A novel proteolytic cascade generates an extracellular matrix-derived chemoattractant in chronic neutrophilic inflammation. J Immunol. 2008 ; 180: 5662-5669.